TY - JOUR
T1 - Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
AU - Solante, Rontgene
AU - Alvarez-Moreno, Carlos
AU - Burhan, Erlina
AU - Chariyalertsak, Suwat
AU - Chiu, Nan Chang
AU - Chuenkitmongkol, Sunate
AU - Dung, D. V.
AU - Hwang, Kao Pin
AU - Ortiz Ibarra, Javier
AU - Kiertiburanakul, Sasisopin
AU - Kulkarni, Prasad S.
AU - Lee, Christopher
AU - Lee, Ping Ing
AU - Lobo, Rommel Crisenio
AU - Macias, Alejandro
AU - Nghia, Cao Huu
AU - Ong-Lim, Anna Lisa
AU - Rodriguez-Morales, Alfonso J.
AU - Richtmann, Rosana
AU - Safadi, Marco Aurélio Palazzi
AU - Satari, Hindra Irawan
AU - Thwaites, Guy
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Areas covered: Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Expert opinion: Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.
AB - Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Areas covered: Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Expert opinion: Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.
KW - AZD1222
KW - booster
KW - CoronaVac
KW - COVID-19
KW - mRNA
KW - omicron
KW - severe
KW - vaccine effectiveness
KW - waning immunity
UR - http://www.scopus.com/inward/record.url?scp=85142148414&partnerID=8YFLogxK
U2 - 10.1080/14760584.2023.2143347
DO - 10.1080/14760584.2023.2143347
M3 - Review article
C2 - 36330971
AN - SCOPUS:85142148414
SN - 1476-0584
VL - 22
SP - 1
EP - 16
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 1
ER -